Skip to content Skip to footer
Subscribe Now
Snap Bio & Monarch Therapeutics
News

SNAP Biosciences Licenses Monarch Therapeutics’ Technology to Advance Snap-Car NK Cell Therapy for Cancer Targets

Shots:SNAP Biosciences & Monarch Therapeutics have entered into a licensing agreement for Monarch’s small molecule adaptor tech to develop & commercialize SNAP's Snap-Car NK cell therapy platform in oncology  Financial terms remain undisclosed but incl. an upfront licensing payment, future development milestones, with net sales-based royaltiesMonarch’s tech enables SNAP-CAR cells to be…
1 day ago

Read more

Genentech & Orionis
News

Genentech Collaborates with Orionis to Identify and Develop Molecular Glue Therapies for Cancer Targets

Shots:Genentech has entered into a multi-year collaboration with Orionis to discover small-molecule monovalent glue drugs for novel & difficult oncology targets using Orionis’ Allo-Glue platformAs per the deal, Orionis will receive $105M upfront & ~$2B in research, development, commercial, & sales milestones, with tiered royalties; Orionis will lead discovery & optimization, while Genentech…
May 22, 2025

Read more

AbbVie & ADARx Pharmaceuticals
News

AbbVie Partners with ADARx Pharmaceuticals to Develop siRNA Therapies Across Multiple Disease Areas

Shots:AbbVie has entered into collaboration & license option agreement with ADARx to develop siRNA therapeutics across multiple disease areas, incl. neuroscience, immunology & oncology, leveraging ADARx's RNA techAs per the deal, ADARx will receive $335M upfront & will be eligible to receive several billion in additional contingent payments incl. option fees, milestones, plus tiered royalties…
May 15, 2025

Read more

Viverita and Boehringer Ingelheim
News

ViVerita Therapeutics Collaborates with Boehringer Ingelheim to Accelerate Discovery of Novel Therapeutic Targets in Oncology

Shots:ViVerita Therapeutics & BI have entered into a strategic research collaboration to accelerate discovery & validation of novel cancer targets. Although financial terms of the deal were not disclosedAs per the deal, ViVerita will utilize its in vivo CRISPR discovery platform to study selected potential targets from BI, evaluating their functions in physiologically relevant…
May 8, 2025

Read more

Mosaic Therapeutics & Astex Pharmaceutical
News

Mosaic Therapeutics In-Licenses ASTX029 & ASTX295 from Astex Pharmaceuticals for Combination Therapy Development for Oncology

Shots:Mosaic has in-licensed ASTX029 & ASTX295 from Astex (Otsuka Pharmaceutical’s subsidiary) to develop combination therapies using these assets, with the 1st combination study expected to begin in 2026As per the deal, Astex granted Mosaic exclusive rights to develop combination products for pts with limited therapy options, receiving a 19% equity stake upfront &…
April 24, 2025

Read more

Netramark & Worldwide Clinical Trials
News

NetraMark Join Forces with Worldwide Clinical Trials to Redefine Clinical Trial Design Using NetraAI Platform

Shots:NetraMark and Worldwide Clinical Trials have entered into a global agreement to utilize NetraMark’s NetraAI platform to advance clinical trial designAs per the deal, NetraAI will initially support P-II neuroscience & oncology trials, plus select P-III studies conducted by Worldwide, with broader access extended to Worldwide’s sponsors across all therapeutic areas & trial…
April 4, 2025

Read more

AstraZeneca & Alteogen
News

AstraZeneca and Alteogen Enter an Exclusive License Deal for ALT-B4 to Develop & Market Subcutaneous Formulations of Multiple Oncology Drugs

Shots:Alteogen has granted AstraZeneca global rights of ALT-B4 to develop & commercialize SC formulations of multiple oncology assets, while Alteogen will be responsible for clinical & commercial supply of ALT-B4 As per the deal, Alteogen will receive an upfront, along with development, regulatory, & sales milestones, plus royalties on sale of commercialized products…
March 17, 2025

Read more

News

Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M

Shots:Sun Pharma to acquire Checkpoint Therapeutics for ~$355M to strengthen its onco-derm innovative portfolio with Unloxcyt (cosibelimab-ipdl); closing expected in Q2’25 As per the deal, Checkpoint stockholders will get $4.10 cash/share (~66% premium) upfront & CVR/share without interest allowing stockholders to receive additional $0.70 cash/share if Unloxcyt is approved before certain deadlines in…
March 10, 2025

Read more

A Complete Account of EMA Approvals in 2024
INSIGHTS+

A Complete Account of EMA Approvals in 2024

Shots:  In 2024, EMA approved around 53 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, vaccines, diagnostic agents, pneumology, nephrology, hepatology, ophthalmology, and endocrinology  PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, &…
March 6, 2025

Read more

Magnet Biomedicine & Eli Lilly
News

Magnet Biomedicine Partners with Eli Lilly to Advance Molecular Glue Therapeutics in Oncology

Shots:Magnet Biomedicine & Eli Lilly have entered into a collaboration & license agreement to identify, develop & commercialize molecular glue therapeutics in oncology using Magnet's TrueGlue discovery platform As per the deal, Magnet will get ~$40M in upfront, near-term payments & equity, plus more than $1.25B in milestones across development, regulatory, & commercial…
March 3, 2025

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]